CN115605228A - 一种特异性结合cd137的制剂及其用途 - Google Patents

一种特异性结合cd137的制剂及其用途 Download PDF

Info

Publication number
CN115605228A
CN115605228A CN202180028568.2A CN202180028568A CN115605228A CN 115605228 A CN115605228 A CN 115605228A CN 202180028568 A CN202180028568 A CN 202180028568A CN 115605228 A CN115605228 A CN 115605228A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
formulation
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028568.2A
Other languages
English (en)
Inventor
张欣
董艳荣
彭建建
付凯
王丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shihuida Pharmaceuticals Group (JILIN) Ltd
Original Assignee
Dingfu Biotarget Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dingfu Biotarget Co ltd filed Critical Dingfu Biotarget Co ltd
Publication of CN115605228A publication Critical patent/CN115605228A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

本申请提供一种制剂，其包含特异性结合CD137的抗体或其抗原结合片段，其中所述CD137抗体包含轻链可变区VL和重链可变区VH，其中所述VL包含SEQ ID NO:1‑11中任一项所示的氨基酸序列；所述VH包含SEQ ID NO:12‑22中任一项所示的氨基酸序列。本申请还提供包含所述制剂的试剂盒，以及所述制剂或所述试剂盒在制备药物中的用途，所述药物用于治疗癌症。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180028568.2A 2020-04-17 2021-04-15 一种特异性结合cd137的制剂及其用途 Pending CN115605228A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010305482 2020-04-17
CN2020103054827 2020-04-17
PCT/CN2021/087582 WO2021209017A1 (zh) 2020-04-17 2021-04-15 一种特异性结合cd137的制剂及其用途

Publications (1)

Publication Number Publication Date
CN115605228A true CN115605228A (zh) 2023-01-13

Family

ID=78084661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028568.2A Pending CN115605228A (zh) 2020-04-17 2021-04-15 一种特异性结合cd137的制剂及其用途

Country Status (5)

Country Link
US (1) US20230285555A1 (zh)
EP (1) EP4137155A1 (zh)
JP (1) JP2023522024A (zh)
CN (1) CN115605228A (zh)
WO (1) WO2021209017A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN107921104A (zh) * 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
AU2016249395B2 (en) * 2015-04-17 2022-04-07 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-PD-1 antibody and another antibody
US10875926B2 (en) * 2015-09-22 2020-12-29 Dingfu Biotarget Co., Ltd. Fully human antibody against human CD 137
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit

Also Published As

Publication number Publication date
US20230285555A1 (en) 2023-09-14
WO2021209017A1 (zh) 2021-10-21
EP4137155A1 (en) 2023-02-22
JP2023522024A (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
KR102679632B1 (ko) 신규한 항_cd137 항체 및 이의 용도
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
JP7073487B2 (ja) 操作された抗体化合物およびこれらの抱合体
JP7102670B2 (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP6577016B2 (ja) 治療及び診断のための抗コラーゲン抗体
CN113896789A (zh) 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
JP7433236B2 (ja) 抗葉酸受容体１抗体及びその使用
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
JP2022522344A (ja) 高親和性抗ｍｅｒｔｋ抗体およびその使用
EP4209513A1 (en) Anti-vegf-anti-pd-l1 bispecific antibody, pharmaceutical composition of same, and uses thereof
CN112955221A (zh) 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
KR20200032156A (ko) 항-tim-3 항체 및 이의 용도
CA3117429A1 (en) Anti-tim-3 antibodies
JP2022511311A (ja) ヒトｐｄ‐ｌ１抗体
CN112794911A (zh) 人源化抗叶酸受体1抗体及其应用
WO2021168169A1 (en) Anti-baff receptor antibodies and uses thereof
US20240124606A1 (en) Anti-cd73 monoclonal antibodies
CN115605228A (zh) 一种特异性结合cd137的制剂及其用途
KR20230167025A (ko) 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도
US20240190955A1 (en) Composition comprising an ige antibody
WO2024062101A1 (en) Bi-specific agent for targeted plasma cell-depletion and treatment of anti-viral immunodeficiency
EP4393506A1 (en) Pharmaceutical composition of anti-il4r antibody and use thereof
CN117203237A (zh) 包含IgE抗体的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078583

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240910

Address after: No. 999, High tech Industrial Park, Baishan City, Jilin Province, China

Applicant after: SHIHUIDA PHARMACEUTICALS GROUP (JILIN) Ltd.

Country or region after: China

Address before: 2nd and 3rd floors, auxiliary building, Wanlong Building, No. 29 Xinfa Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, China 215127

Applicant before: DINGFU BIOTARGET Co.,Ltd.

Country or region before: China